MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ
8.20
+0.15
+1.81%
Closed 16:00 03/27 EDT
OPEN
8.08
PREV CLOSE
8.05
HIGH
8.28
LOW
8.08
VOLUME
2.69K
TURNOVER
0
52 WEEK HIGH
17.60
52 WEEK LOW
5.22
MARKET CAP
24.27M
P/E (TTM)
-0.6107
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ONCT last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at ONCT last week (0311-0315)?
Weekly Report · 03/18 11:58
Weekly Report: what happened at ONCT last week (0304-0308)?
Weekly Report · 03/11 11:54
Oncternal Therapeutics files for mixed shelf offering
Oncternal Therapeutics files for mixed shelf offering without disclosing the amount. The company filed a prospectus related to a proposed mixed shelf offer. OncternalTherapeutics, Inc. (ONCT) stock. The stock is down 2.7% in the last week.
Seeking Alpha · 03/08 21:52
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Joint (JYNT) and Xtant Medical Holdings (XTNT) have received a lot of coverage today. Craig-Hallum analyst Jeremy Hamblin reiterated a Hold rating on Joint today. Oncternal Therapeutics (ONCT) has been upgraded to Buy.
TipRanks · 03/08 13:50
Oncternal Therapeutics Inc: Annual report
Press release · 03/08 04:16
Oncternal Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Oncternal Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $3.11 per share. Revenue rose 73.7% to $297.00 thousand from the same quarter last year. The mean expectation of four analysts was for a loss of £3.07.
Reuters · 03/07 23:33
Press Release: Oncternal Therapeutics Provides -2-
Clinical outcomes may materially change as patient enrollment continues; and other risks described in Oncternal's filings with the U.S. Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date of this release. The company's shares are trading on the New York Stock Exchange.
Dow Jones · 03/07 21:01
More
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Webull offers Oncternal Therapeutics Inc stock information, including NASDAQ: ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.